Tibotec Pharmaceuticals Ltd.

Janssen R&d Ireland

Medivir Ab

Janssen Sciences Ireland Uc

Tibotec Bvba

Tibotec Pharmaceuticals Ltd. Co

Wim Van De Vreken

Pierre Jean-Marie Bernard Raboisson

Herman Augustinus De Kock

Sandrine Marie Helene Vendeville

Dominique Louis Nestor Ghislain Surleraux

Abdellah Tahri

Lili Hu

Kenneth Simmen

David Craig McGowan

Bart Rudolf Romanie Kesteleyn

Pierre Jean-Marie Raboisson

Piet Tom Bert Paul Wigerinck

Bengt Bertil Samuelsson

Karl Magnus Nilsson

Hans Kristian Wallberg

Kurt Hertogs

David Craig Mc Gowan

Maxime Francis Jean-Marie Ghislain Canard

Annick Ann Peeters

Eva Bettens

Ismet Dorange

Natalie Maria Francisca Kindermans

Yvan Simonnet

Veronique Corine Paul De Vroey

Dirk Edward Désiré Jochmans

Kenneth Alan Simmen

ÅSa Annica Kristina Rosenquist

Jing Wang

Inhibitors of HCV replication of formula (I) and the salts and stereoisomers thereof, wherein

Macrocyclic inhibitors of hepatitis C virus

Inhibitors of HCV replication of formula (I) whereinW is a heterocycle of formula and the remaining variables are as defined in the specification.

Inhibitors of HCV replication of formula (I) wherein and the remaining variables are as defined in the specification.

Macrocylic inhibitors of hepatitis C virus

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein each variable has specific definitions. Pharmaceutical compositions containing compounds (I) and process for preparing compounds (I) are also provided. Bioavailable combinations of the inhibitors of HCV of Formula (I) with ritonavir are also provided.

4-substituted 1,5-dihydro-pyrido[3,2-b]indol-2-ones of formula (I): the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein n is 1, 2 or 3; 

Derivatives of 1-phenyl-benzofuro[3,2]pyridin-2(1H)-one

The present invention concerns the compounds of formula (I) their N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites, wherein n is 1, 2 or 3; Ris H, CN, halo, aminoC(&#x2550;O), C(&#x2550;O)OH, CalkyloxyC(&#x2550;O), CalkylC(&#x2550;O), mono- or di(Calkyl)aminoC(&#x2550;O), arylaminoC(&#x2550;O), N-(aryl)-N&#x2014;(Calkyl)aminoC(&#x2550;O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(Calkyl)methanimidamidyl, Hetor Het; Ris H, Calkyl, Calkenyl, Ccycloalkyl, wherein said Calkyl, Calkenyl and Ccycloalkyl may be optionally substituted; Ris nitro, cyano, amino, halo, hydroxy, Calkyloxy, hydroxyC(&#x2550;O), aminoC(&#x2550;O), CalkyloxyC(&#x2550;O), mono- or di(Calkyl)aminoC(&#x2550;O), CalkylC(&#x2550;O), methanimidamidyl, mono- or di(Calkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het; for use as a medicine. The invention further relates to a novel subgroup of the compounds of formula (I), and to compositions comprising compounds of formula (I).

Substituted indolepyridinium as anti-infective compounds

HIV inhibitory compounds of formula: salts and stereoisomers thereof, wherein n is 1, 2 or 3;

1,5,6,-substituted-2-oxo-3-cyano-1,6a-diaza-tetrahydro-fluoranthenes as anti-inflective agents

Growing community of inventors

Beveren, Belgium

Wim Van De Vreken